Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non–small cell lung cancer (NSCLC), surgical resection remains the treatment of choice with adjuvant chemotherapy. In a recent study published in the...
Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers that have reached the lymph nodes. The radioactive dye technetium Tc-99m...
The overexpression or underexpression of a newly identified set of genes related to lipid metabolism may help physicians identify whether or not a woman is at risk for hormone receptor–positive or hormone receptor–negative breast cancer and to subsequently tailor prevention strategies...
Amgen has announced results from a phase III trial evaluating the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Talimogene...
Humans have between 20,000 and 25,000 genes that carry instructions for assembling the proteins that do the work of cells. Work led by St. Jude Children’s Research Hospital found that children who inherit certain variations in four particular genes are at much higher risk of developing acute...
The National Comprehensive Cancer Network (NCCN) announced today the addition of two new NCCN Member Institutions: UC San Diego Moores Cancer Center in La Jolla, California, and the University of Colorado Cancer Center in Aurora, Colorado. "We are extremely pleased that UC San Diego Moores Cancer...
The National Comprehensive Cancer Network (NCCN) has issued its first ever NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Survivorship. The new NCCN Guidelines were presented at the NCCN 18th Annual Conference: Advancing the Standard of Cancer Care by Panel Chair, Crystal S....
Women are 30% less likely to die of ovarian cancer if they have guideline-recommended treatment, yet nearly two-thirds of those with the disease do not receive it, often because they are cared for at hospitals that treat a small number of ovarian cancer patients. These are the findings of a study...
Patients with advanced ovarian cancer who undergo intensive treatment with chemotherapy that bathes the abdomen are significantly more likely to live longer than those who receive standard intravenous (IV) chemotherapy, according to a study that analyzed long-term follow-up from two landmark...
The FDA has approved technetium Tc 99m tilmanocept (Lymphoseek Injection), a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes. Technetium Tc 99m tilmanocept is an...
Two Indiana University researchers have been awarded a multiyear, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States. Mark R. Kelley, PhD, Betty and Earl Herr Professor of Pediatric Oncology Research, and Melissa ...
Endometrial cancer survivors are more likely to complete physical activity, and for longer durations, when their daily self-efficacy is higher, according to a study published online in the journal Health Psychology, a publication of the American Psychology Association. “Sedentary behavior is ...
Combatting the tobacco industry’s tactics in the world’s poorest countries as well as ensuring the best cancer vaccines are available to those most in need are key in order to reduce the number of cancer deaths worldwide, according to a new report published in the journal Science...
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a...
New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need adjuvant chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive...
The American Association for Cancer Research (AACR) reported with sadness the loss of Zora Brown, a trustee for the AACR Foundation for the Prevention and Cure of Cancer, a breast and ovarian cancer survivor, and a pioneering advocate for cancer research and breast cancer awareness among...
Researchers at Moffitt Cancer Center and colleagues have found that healthy adolescent females have predetermined expectations for becoming parents in the future, but have concerns about fertility and childbearing should they develop a life-threatening illness, such as cancer. The...
In a significant advance for harnessing the immune system to treat leukemias, researchers at Fred Hutchinson Cancer Research Center have successfully infused large numbers of donor-derived T cells specific for a key antileukemic antigen in order to prolong survival in high-risk and relapsed...
An increasing body mass index (BMI) was associated with a higher risk for colorectal cancer with a specific molecular characteristic, and inversely, physical activity was linked to a decreased risk for that same cancer, according to data published in Cancer Research, a journal of the American...
Women who have had the lymph nodes under their arm surgically removed during breast cancer treatment are warned to avoid certain practices that can cause lymphedema. Now, a new study published in the March issue of the Journal of the American College of Surgeons suggests that the vast majority of...
An international research team co-led by cancer prevention researcher Ulrike Peters, PhD, MPH, and biostatistician Hsu Li, PhD, at Fred Hutchinson Cancer Research Center has identified variations in four genes that are linked to an increased risk of colorectal cancer. Dr. Peters and...
A new drug combination shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included preclinical and clinical analyses, were published in Clinical Cancer Research, a journal...
Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, but the disease is exceptionally difficult to treat when front-line therapy fails. "After surgery, with or without presurgical chemotherapy, when low-grade serous ovarian cancer persists or returns,...
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy. The findings, by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and...
The FDA approved pomalidomide (Pomalyst) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Pomalidomide, an oral immunomodulatory agent, is intended for patients who have received at least two prior therapies, including lenalidomide...
Laboratory experiments conducted by researchers at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the investigational agent ibrutinib and bortezomib (Velcade) could potentially be an effective new therapy for several forms of blood cancer, including...
After an intensive 3-year hunt through the genome, researchers have pinpointed mutations that lead to drug resistance and relapse in acute lymphoblastic leukemia (ALL) ,the most common type of childhood cancer—the first time anyone has linked the disease’s reemergence to specific...
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial. The...
In a major breakthrough for uterine serous carcinoma (USC), a chemoresistant, aggressive form of endometrial cancer, researchers at Yale Cancer Center have defined the genetic landscape of USC tumors, findings that point to new treatment opportunities. The collaborative team, which included...
Reporting the results of a phase I clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of vorinostat (Zolinza) in combination with another round...
The FDA approved a new use of imatinib (Gleevec) to treat children newly diagnosed with Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). ALL is the most common type of pediatric cancer, affecting approximately 2,900 children annually, and progresses quickly if untreated....
Research led by St. Jude Children’s Research Hospital scientists has identified a possible lead in treatment of two childhood leukemia subtypes known for their dramatic loss of chromosomes and poor treatment outcomes. The findings also provide the first evidence of the genetic basis for ...